AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product
Under the agreement, AGC Biologics is providing autologous production for a next-generation-therapy product focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials.
- Under the agreement, AGC Biologics is providing autologous production for a next-generation-therapy product focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials.
- With the product currently in the pre-clinical phase, AGC Biologics will perform a process transfer and clinical manufacturing of Medigene’s product candidate at the CDMO’s Cell and Gene Center of Excellence in Milan.
- Although complex to manufacture, they offer unique therapeutic effects for patients in need,” said Luca Alberici, General Manager of AGC Biologics Milan.
- AGC Biologics' Milan location has 30 years of experience in the cell and gene field and expertise with complex advanced cell therapy projects, such as these.